ANN ARBOR, Mich., June 16, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has filed a prospectus supplement to sell shares of its common stock, no par value per share, at an aggregate offering amount of approximately $20 million through an "at-the-market" (ATM) offering. If utilized, the shares would be offered through McNicoll, Lewis & Vlak LLC (MLV) as sales agent who, at Aastrom's discretion and instruction, will use its commercially reasonable efforts to sell the shares at market prices from time to time, including sales made by means of ordinary brokers' transactions on the NASDAQ Capital Market.
